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Abstract
Background: In keeping with the fundamental practice of transparency in the discussion and resolution of ethics
conflicts raised by research, a summary of ethics issues raised during Portuguese biomonitoring in health surveillance and
research is presented and, where applicable, their resolution is described.
Methods: Projects underway aim to promote the surveillance of public health related to the presence of solid waste
incinerators or to study associations between human exposure to environmental factors and adverse health effects. The
methodological approach involves biomonitoring of heavy metals, dioxins and/or other persistent organic pollutants in
tissues including blood, human milk and both scalp and pubic hair in groups such as the general population, children,
pregnant women or women attempting pregnancy. As such, the projects entail the recruitment of individuals
representing different demographic and health conditions, the collection of body tissues and personal data, and the
processing of the data and results.
Results: The issue of autonomy is raised during the recruitment of participants and during the collection of samples and
data. This right is protected by the requirement for prior written, informed consent from the participant or, in the case
of children, from their guardian. Recruitment has been successful, among eligible participants, in spite of incentives rarely
being offered. The exception has been in obtaining guardians' consent for children's participation, particularly for blood
sampling. In an attempt to mitigate the harm-benefit ratio, current research efforts include alternative less invasive
biomarkers.
Surveys are currently being conducted under contract as independent biomonitoring actions and as such, must be
explicitly disclosed as a potential conflict of interests. Communication of results to participants is in general only practised
when a health issue is present and corrective action possible. Concerning human milk a careful approach is taken,
considering breast-feeding's proven benefits.
Conclusion: No national legislation currently accounts for the surveillance component of biomonitoring as distinct from
research. Ethics issues arising within the domain of research are resolved according to available regulations. For issues
encountered during surveillance, the same principles are used as guidance, completed by the authors' best judgement and
relevant ethics committees' findings.
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Background
Transparency is of fundamental importance in the discus-
sion and resolution of ethics problems raised within sci-
entific practice, besides being an ethical requirement
itself. It is important that ethical challenges, solutions and
evaluation of those solutions are documented [1], not
only as an ethical responsibility [2], but also in order to be
able to refute accusations of improper conduct and to
inform other researchers facing the same issues in similar
or follow-up research. As a recent science which is devel-
oping rapidly under the growing attention that the field of
Environmental Health is attracting, human biomonitor-
ing (HBM) is a case in point. Both its overlap of the fields
of medicine and environmental sciences and the difficulty
in categorically classifying it as any of the classical epide-
miological study designs, further mean a lack of compara-
ble experience and correspondingly, of any existing legal
framework.
In this regard, it is the authors' objective to disclose the
main ethics issues encountered during human biomoni-
toring conducted in Portugal and describe how they have
been handled and/or solved.
Methods
The authors' current biomonitoring projects, hereby
referred to by their Portuguese acronyms, include
ProVEpA, which involves biomonitoring of dioxin-like
compounds and heavy metals, in tissues including blood
and pubic hair, in the general population and pregnant
women; monitoring of lead and mercury in blood and
hair in children; and monitoring of dioxin-like com-
pounds in human milk, and having involved approxi-
mately 1,700 participants in both Lisbon and Madeira
since 1999. Its main aim is the surveillance of the effects
of the proximity of municipal solid-waste incinerators on
levels of the potentially most harmful substances released
during the process of incineration. Temporal trends of
these levels are also monitored, as are potential adverse
health effects in neighbouring populations.
Recruitment strategies have evolved since the start of the
study. Currently, general population adults are recruited
among blood donors through collaboration with the
national institute for blood collection which allows the
authors' team to accompany its mobile units. Pregnant
women are recruited at ante-natal appointments in mater-
nities or, when umbilical cord blood and pubic hair sam-
ples are required as opposed to venous blood, in pre-
labour in obstetric wards. They are often followed through
and further donate human milk samples. Recruitment of
children aged one to six years is performed in hospitals
and primary health-care centres. For blood sampling, tar-
geted children are those scheduled to draw blood for
other purposes, whereas for hair sampling a hair-cut is
purposely arranged.
In all of these groups recruitment is only conducted
among apparently healthy individuals and equal numbers
of age and (when relevant) gender-paired residents or
workers in the areas of study and control areas are
enrolled. For children, age groups are targeted in order
that ages 12–24 and 25–36 months are 50% over-repre-
sented as compared to older groups.
The project entitled VAEDA involves the monitoring of
blood lead and dioxin-like compounds and their poten-
tial association with the incidence of miscarriage and aims
to enrol 200 women in Lisbon and Madeira. The recruit-
ment strategy of VAEDA involved setting up a toll-free call
centre and widely disseminating details of the study
including its phone number, in order to reach the specific
target population of women trying, or about to try, to
become pregnant. Dissemination has comprised TV
reports and interviews, articles in newspapers and maga-
zines, raising awareness among primary health care work-
ers and the distribution of flyers and posters in primary
health-care centres, maternities, pharmacies, shops and
hairdressers.
Following a World Health Organization (WHO) protocol
[3], another study monitors twelve persistent organic pol-
lutants in human milk and geographically representative
sampling is being achieved through local recruitments by
family health doctors in primary health-care centres.
The authors' most recent study is FEXHE-BIO, determin-
ing foetal exposure to lead and correlation with environ-
mental indicators including lead in moss and topsoil.
Here recruitment of apparently healthy pregnant women
resident in Central Portugal for at least 5 years is ensured
by a national network of hospitals and maternities.
In all studies participation involves a tissue or fluid collec-
tion procedure, accompanied by a questionnaire and a
written informed consent form. It is generally a once-off
event, with the only exceptions being annual sampling
performed for general population adults in Madeira, and
daily urine collection during three menstrual cycles for
women attempting pregnancy in VAEDA. No medical
records are consulted and all requested health informa-
tion is provided by the participant, of their own free will.
Written informed consent is obtained in all studies con-
ducted. It includes a brief explanation of aims, benefits
and requirements of participation, an explanation that
withdrawal of consent is permitted at any time and an
assurance of the confidentiality of data collected.Environmental Health 2008, 7(Suppl 1):S5 http://www.ehjournal.net/content/7/S1/S5
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Results are communicated to participants only when their
readings are outside the normal range towards levels con-
sidered adverse to health, with the exception of pregnancy
monitoring in VAEDA, whose results will be imparted at
the end of the study.
Compensation is generally not provided in return for par-
ticipation. The exceptions are, for participants in the
ProVEpA project, the provision of routine blood tests to
general population adults and of vouchers for hair-cuts to
children, which simultaneously serve the purpose of hair
sampling. Participants in VAEDA are offered the opportu-




Autonomy is one of the basic ethical principles governing
all research involving human subjects. It upholds the sub-
jects' right to be fully informed and free to decide whether
they wish to participate [4] and underlies the requirement
for situated Informed Consent. However, groups with
diminished autonomy, such as children, though impeded
from providing consent in these terms, cannot ethically be
excluded from research, as often they are among the most
vulnerable and at-risk groups and as such are afforded
specific protection under national law [5]. The responsi-
bility for the protection of their rights is shifted to their
guardians, with the researchers also accountable through
their code of ethics.
Increasingly, in research involving children, the assent of
the child is required, in addition to the informed consent
of one or both parents/guardians. This involves a child's
affirmative agreement to participate in the research and
not mere failure to object [6]. Although assent of the child
is not explicitly defined or required by law, their rights are
assured by national law [7,8] and the European Conven-
tion on Human Rights and Biomedicine determines, in
the context of health interventions, that the opinion of the
minor must be taken into consideration in proportion to
their age and maturity [9]. Children, during gestation and
after birth, form an important component of the authors'
research. This results from a decision implicitly prioritiz-
ing the protection of a vulnerable group over their right to
self-determination.
The afore-mentioned Convention also defines that
research may only be carried out on a person who does
not have the capacity to consent if "the results of the
research have the potential to produce real and direct ben-
efit to his or her health" unless "the research has the aim
of contributing, through significant improvement in the
scientific understanding of the individual's condition, dis-
ease or disorder, to the ultimate attainment of results
capable of conferring benefit to the person concerned or
to other persons in the same age category or afflicted with
the same disease or disorder or having the same condi-
tion"[9]. Although the latter validates research activities in
biomonitoring, surveillance is not encompassed in the
definition of research as the production of new, generaliz-
able knowledge, as distinct from knowledge pertaining
only to a particular individual or programme [10]. How-
ever this borders on a semantic issue in that surveillance
equally aims to contribute to the scientific understanding
of individuals' condition, with the ultimate aim of confer-
ring benefit to the person concerned or others in the same
condition by providing information which can be linked
to health effects. As such, it is the authors' best interpreta-
tion that surveillance should be guided by this legislation
in addition to pondering input from the relevant health
ethics committees and other bodies.
Beneficence
The principle of doing good [2,4], or maximizing benefits
over harms [10] and non-maleficence, the principle of not
harming, inherent to the field of health-care, can become
a surprisingly contentious issue in public health, in that
the latter is principally concerned with community health,
whose interests occasionally collide with the interests of
health or well-being of individuals. An interesting exam-
ple is vaccination: in diseases which are nearly eliminated,
incidence of adverse effects is in some cases greater than
morbidity of the disease itself, yet elimination is obvi-
ously in the public's interests.
Biomonitoring is even more debatable in that direct
health benefits are only occasionally produced, for exam-
ple when levels detected are in the range of those known
to affect health and remedial action is possible. Where
biomonitoring involves research into the health effects of
a substance's body burden, health benefits are indirect
and not immediate.
Invasive sampling techniques such as blood withdrawal
pose a small but not insignificant risk to an individual's
health, which in the context of research is generally judged
to be outweighed by the greater community good.
In the context of children's participation, requesting altru-
istic actions from an individual who cannot provide true
informed consent is ethically debatable however, not-
withstanding the nobility of the principle of protecting
the vulnerable.
In legislative terms, the situation is equally contradictory,
with the European Convention on Human Rights stating
that "the interests and welfare of the human being shall
prevail over the sole interest of society or science", yet
foreseeing restrictions to this "in the interest of publicEnvironmental Health 2008, 7(Suppl 1):S5 http://www.ehjournal.net/content/7/S1/S5
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safety, for the prevention of crime, for the protection of
public health or for the protection of the rights and
freedoms of others" [9].
The authors' current research includes attempts to corre-
late hair and blood heavy metal levels in children, to
determine if the less invasive technique with hair samples
could replace the need for blood sampling. Similarly,
pubic hair from pregnant women at the time of birth is
collected and analysed for correlation with blood heavy
metal levels.
Other ethics issues related to recruitment and sample 
collection
The lack of any immediate benefit for the participant,
while not in itself a deterrent, does not on the other hand
constitute an incentive to voluntary participation. Added
to the fact that individuals should not be pressured to par-
ticipate in a study [10], recruitment can often constitute a
limiting factor. Whereas payment for participation is
often deemed unethical and may even be illegal [9],
"compensation" for time lost or travel expenses is accept-
able practice. Our experience of performing and reporting
routine blood tests as a bonus has proven successful in the
ProVEpA project in recruiting participants from the gen-
eral population. Refusals to participate are extremely rare
in this group, mainly due to the fact that recruitment is
currently performed among blood donors and participa-
tion implies only a small increase in the volume of blood
withdrawn. The strategy of approaching subjects who are
drawing blood for other purposes has also proven success-
ful in recruiting pregnant women, in both ProVEpA and
FEXHE-BIO, with few refusals reported.
Recruitment of children has been problematic however,
and medical appointments have not proven to be success-
ful recruiting-ground, not only because the children are
frequently accompanied by an adult other than a parent,
who are understandably less willing to provide consent,
but also because the parents themselves will often not
allow blood withdrawal solely for monitoring purposes if
it is not otherwise required for medical reasons. Obtain-
ing hair samples from the children has posed the least
problems and the compensation strategy of providing
vouchers for corrective hair-cuts has proven popular. An
initial attempt at recruiting children from pre-school facil-
ities was abandoned after, in addition to parents' reti-
cence, staff expressed concerns about the children
associating the negative experience of blood withdrawal
with the location, aggravating the unwillingness many
children already displayed in attending. This was upheld
as a valid ethical concern.
Consent has also not been the obstacle to obtaining pubic
hair from pregnant women as they are recruited in pre-
labour in obstetric wards prior to routine pubic shaving.
Differences in grooming habits between regions have led
to women in Lisbon providing insufficient hair for these
analyses to continue while in Madeira this problem has
not arisen and sampling is still in place.
Donation of umbilical cord blood for sampling in
ProVEpA provides useful estimates of maternal pollutant
load and of foetal exposure, but decreases in adhesion
rates forced the practice to be dropped in Lisbon,
although still ongoing in Madeira. A contributing factor is
thought to be the increase in the number of parents cryo-
preserving umbilical cord stem cells in private bio-banks
for future health-care options for their child, an interest-
ing ethical issue itself [11].
The non-targeted recruitment strategy of VAEDA, where
potential participants contact a toll-free call centre of their
own initiative, enables records of contacts made and sub-
sequent participation to be kept, with a current recruit-
ment rate of 44%. The main reasons for not participating
include non-eligibility and misunderstanding of study
aims. The strategy also guarantees a low refusal rate – just
13% of women who contact the call-centre but do not end
up participating.
Health-care worker involvement in recruitment has
proven one of the most successful strategies, in both
VAEDA and FEXHE-BIO, due to their direct contact with
the pool of potential participants which means a greater
number can be approached and also to the professional
relationship of trust, which improves rates of consent.
Media participation in publicizing the projects has been
invaluable in studies such as VAEDA which involve
recruitment addressed to an extremely specific population
sub-group (healthy women attempting to become preg-
nant). A broader dissemination of the aims and results of
HBM needs to be undertaken as a priority, not only as rais-
ing public awareness should increase participation rates,
but also in the interests of openness and transparency.
Conflicts of interests
Any agency performing independent intervention evalua-
tion/consultancy is faced with a potential conflict of inter-
est. ProVEpA is conducted as a surveillance study of
human exposure to the most critical pollutants of solid-
waste incinerators and potentially associated health
effects in populations residing in their vicinities, commis-
sioned by waste management companies Valorsul and
Valor Ambiente. The study is therefore financed by enti-
ties that have obvious vested interests in the outcome of
the study. Ethically, transparency is key, requiring full dis-
closure of the conflict of interest [10] and relying on the
scientific objectivity and impartiality of the researchersEnvironmental Health 2008, 7(Suppl 1):S5 http://www.ehjournal.net/content/7/S1/S5
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and their responsibility to publish findings, independent
of possible negative reactions from any stakeholders,
whether they are public, governmental or industrial [12].
In parallel, a supervisory committee appraises the rigour
and independence of the study and of the contactor-con-
sultancy relationship.
The waste management companies are required, as a fol-
low-up to environmental impact reporting conducted as a
part of the licensing procedure, to carry out Environmen-
tal and Public Health monitoring programs, as risk sur-
veillance and control measures, for the duration of the
facility's life span. This practice was compulsorily imple-
mented in the late nineties in response to public and sci-
entific concerns over the widespread use of incineration,
in an attempt to mitigate the conflict of interests between
the public's right to the safeguarding of their health and to
the proof thereof, and the companies' interests. However,
as with other forms of public health research, evaluation
of results requires careful study of risk-benefit ratios.
Waste incineration is conducted in the public's interests
and is not a purely profit-making industry. Potential neg-
ative impacts of waste incineration on human health must
be weighed against the relative risks to both human health
and environmental quality of alternative methods of
waste disposal and not simply against its absence.
Information practices
Obtaining informed consent is crucial to safeguard the
autonomy of the participants and is obtained in written
form in all studies conducted. It also constitutes an infor-
mation practice since it usually includes a brief explana-
tion of aims, benefits and requirements of participation,
an explanation that withdrawal of consent is permitted at
any time and an assurance of the confidentiality of data
collected. It covers sample collection and handling and
storage and processing of personal data. Consequences
and risks are not generally specified as they are only rele-
vant in the case of blood sampling, and in this case (with
the exception of VAEDA) the participants are drawing
blood irrespectively so possible negative consequences are
not linked to, and as such do not constitute a deterrent
from, participation.
Assent is not obtained from children as a rule due to their
age (one to six years) – in keeping with European law
which states that the opinion of the minor shall be con-
sidered in proportion to their age [9] -, and to their draw-
ing blood for other purposes. Full written informed
consent is invariably required from a parent/guardian.
Besides informed consent prior to the study, reporting of
results also presents another occasion for information to
be made available to participants. The 'right to know' con-
cerning an individual's health information has lately been
supplemented by the 'right not to know', of particular
interest when the health effects of a substance are not
know, or if known, reduction options are not clear. Both
these rights are protected by European Convention [9].
Current participants in ProVEpA, FEXHE-BIO and the
human milk survey are not asked if they wish to be
informed of their results and are only individually
informed if their readings are outside the normal range, in
which case they are informed through their family doctor,
in keeping with the law [13]. VAEDA participants will be
fully informed of their results – incidence of miscarriages
and blood lead and dioxin load – at the end of the project,
and the authors have found this to be the main incentive
for participation, but similarly an information opt-out is
not explicitly offered.
Communicating or not the dioxin or heavy metal load in
human milk (ProVEpA and human milk survey) is a sen-
sitive issue which must be approached particularly care-
fully. The benefits of breast-feeding are so significant that
the WHO has advised that they outweigh any risks result-
ing from exposure of the nursing child to raised pollutant
levels in milk [14]. This must be unambiguously commu-
nicated to mothers when informing them of their raised
pollutant load so that their concerns for the health of their
infant do not lead them to stop breast-feeding. The fact
that human milk samples and pubic hair samples are fre-
quently pooled for analysis (due to lack of sufficient
quantity for individual analysis) further complicates mat-
ters (human milk survey and ProVEpA in Madeira), as
here abnormal values must be reported highlighting the
degree of uncertainty due to the multiple and unknown
contributions of the group elements.
Informed consent forms explicitly state that samples will
only be kept until analysis and no use beyond that ini-
tially predicted and informed to the donor will be made.
Data protection
Data protection is another topic where public interests are
put above the rights of the individuals, namely the right to
privacy [4]. Maintaining data confidentiality is a current
public concern raised, possibly unduly, by increased use
of computerized databases. This topic has been gaining
ever greater attention from researchers and law-makers. In
spite of this, there is still a lack of regulation on specific
aspects in many countries, including Portugal, as can be
seen from the tables on data protection, presented in the
document "Ethics and data protection in a number of
European countries" [15], compiled within the ESBIO
project [16].
In order to be able to communicate individual results, and
to guarantee access to participants for follow-up sampling
in VAEDA and in the human milk survey, volunteers'Environmental Health 2008, 7(Suppl 1):S5 http://www.ehjournal.net/content/7/S1/S5
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identities can not be irreversibly anonymized. However,
as all projects store sensitive data on health, participants'
names are coded prior to data processing and analysis and
database access is protected by user passwords, conform-
ing to legislation on information storage [13]. The secu-
rity and confidentiality of the data stored is ensured by a
number of measures designed to restrict and/or register all
forms of access to participants' personal data including
physical access to facilities, access to databases and other
means of storage and access to means of data insertion
and processing [17].
Besides covering all aspects of sample collection,
informed consent sought from participants also foresees
both the storage and processing of data concerning them.
The guarantee of the confidentiality of this data under any
circumstances is a fundamental part of initial information
practices.
Ethics committees
Although no official opinions from national ethics bodies
have been stated in regard to human biomonitoring [15],
all Portuguese public health institutions have an ethics
committee to which research and surveillance projects
using a HBM approach have to be submitted prior to their
commencement, as any project involving data and sample
collection. All study protocols mentioned were approved
by the University of Lisbon, Faculty of Medicine Ethics
Committee. In addition, projects where recruitment
involved collaborations with other health institutes were
also approved by their respective ethics committees, as
was the case of Dr Alfredo da Costa Maternity where preg-
nant women are recruited in Lisbon and Dona Estefânia
Hospital where children were formerly recruited, and all
the hospitals and maternities collaborating with FEXHE-
BIO's aims of determining foetal exposure to lead.
Appraisals from health ethics committees are not legally
binding [18] but it is accepted practice to conform to the
recommendations made.
Current legislation and constraints
Apart from legislation covering collection of health infor-
mation [13], data protection [17], ethics committees [18],
the basis of national health policy [5] and individuals'
rights [7,8], the only legislation regulating scientific
research involving humans not classified as clinical trials
is the European Convention on Human Rights and Bio-
medicine ratified to national law [9]. In addition, no
national legislation currently accounts for the surveillance
component of biomonitoring as distinct from research, so
ethical issues including those presented here are fre-
quently left to the best judgement of the involved profes-
sionals or ethics committees.
Conclusion
The authors are satisfied that the issues of autonomy and
beneficence are being handled according to ethical princi-
ples, in spite of legislative uncertainty. Current informa-
tion practices require some alterations, particularly as to
the provision of the right to know. Potential misinterpre-
tation of the concept of biobanking in regard to sample
storage for the relatively short period between collection
and analysis means sample storage practices within the
projects underway probably ought to be re-evaluated
according to Article 19 of Law no. 12/2005, dated January
26th [13]. As the most conspicuous ethical issue, the pres-
ence of conflicts of interest has been successfully handled.
Raising the profile of human biomonitoring – which the
upcoming European-scale Pilot Project to develop a
coherent approach to Human Biomonitoring in Europe,
foreseen under the European Commission's Environment
and Health Action Plan 2004–2010 [19], will contribute
to – could have important consequences in terms of pub-
lic awareness, contributing to improved recruitment rates,
and also in legislative terms, thereby clarifying and vali-
dating HBM's standing.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
MFR and JPM designed, organize and/or coordinate all
projects referred to. AB and MM recruit participants and
perform technical and laboratory work for ProVEpA; SS,
HTS and MM for VAEDA; VG for FEXHE-BIO; and AB for
the human milk project. MFR and SS are responsible for
the manuscript text.
Acknowledgements
ProVEpA is conducted under contract for Valorsul and Valor Ambiente.
VAEDA and FEXHE-BIO are both financed by the Fundação para a Ciência 
e a Tecnologia with participation by FEDER, under POCI2010; ref. POCI/
SAU-ESP/58298/2004 (VAEDA) and POCI/SAU-ESP/62115/2004 (FEXHE-
BIO).
This article has been published as part of Environmental Health Volume 7 
Supplement 1, 2008: Ethics and communication in human biomonitoring: 
European perspectives. The full contents of the supplement are available 
online at http://www.ehjournal.net/supplements/7/S1.
References
1. Committee on Human Biomonitoring for Environmental Toxicants,
National Research Council of the National Academies: Human Bio-
monitoring for Environmental Chemicals.  The National Acade-
mies Press, Washington, DC;; 2006. 
2. Deontological Code of the Portuguese Medical Association
(Ordem dos Médicos)   [http://www.ordemdosmedicos.pt/
send_file.php?tid=ZmljaGVpcm9z&did=c81e728d9d4c2f636f067f89c
c14862c]
3. World Health Organization: Fourth WHO-Coordinated Survey
of Human Milk for Persistent Organic Pollutants (POPs):
Guidelines for Developing a National Protocol.   [ h t t p : / /
www.who.int/foodsafety/chem/POPprotocol.pdf].Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Environmental Health 2008, 7(Suppl 1):S5 http://www.ehjournal.net/content/7/S1/S5
Page 7 of 7
(page number not for citation purposes)
4. Last JM: Ethics and Public Health Policy.  In Maxcy-Rosenau-Last
Public Health & Preventive Medicine 14th edition. Edited by: Wallace RB,
Doebbeling BN. Connecticut: Appleton & Lange; 1998:35-43. 
5. Law no. 47/90 dated August 24th. Diário da República –
Series I – no. 195.  .
6. Kon AA: Assent in Pediatric Research.  Pediatrics 2006,
117(5):1806-1810.
7. Constitution of the Republic of Portugal, Seventh constitu-
tional revision.  2005.
8. Portuguese Civil Code, Law decree no. 47344/66 dated
November 25th. Diário da República – Series I – no. 274.  .
9. European Convention on Human Rights and Biomedicine,
ratified to national law as Assembly of the Republic Resolu-
tion n°1/2001.  .
10. Council for International Organizations of Medical Sciences: Interna-
tional Guidelines for Ethical Review of Epidemiological Stud-
ies.  Geneva 1991.
11. Dalle JH: Cord blood banking: public versus private banks-
facts to ponder and consider [in French].  Archives de pédiatrie
2005, 12:298-304.
12. Wing S: Social Responsibility and Research Ethics in Commu-
nity-Driven Studies of Industrialized Hog Production.  Envi-
ronmental Health Perspectives 2002, 110(5):437-444.
13. Law no. 12/2005 dated January 26th. Diário da República
Series I – A – no. 18.  .
14. World Health Organization: Biomonitoring of Human Milk.
[http://www.who.int/foodsafety/chem/POPtechnicalnote.pdf].
15. ESBIO WP4 Report, March 2007: Ethics and data protection
in a number of European countries  2007 [http://www.eu-bio
monitoring.org/doc/esbio_del_wp4.1-4.3.pdf].
16. Expert team to Support BIOmonitoring in Europe (ESBIO)
[http://www.eu-biomonitoring.org/index.htm]
17. Law no. 67/98 dated October 26th, Article 15. Diário da
República Series I – A – no. 247.  .
18. Law Decree no. 97/95 dated May 10th. Diário da República
Series I – A – no. 108.  .
19. Communication from the Commission to the Council, the European
Parliament, the European Economic and Social Committee: " The
European Environment & Health Action Plan 2004–2010".
Brussels, 9.6.2004; COM(2004) 416 final .